Merck sees promising results in trial of COVID-19 pill, will apply for emergency approval from FDA
Merck on Friday said it will seek emergency approval of an antiviral pill to treat COVID-19 after it significantly cut the risk of bad outcomes in clinical trials.
The New Jersey-based drugmaker said the drug, molnupiravir, cut the risk of hospitalization or death in half in high-risk patients with mild to moderate illness.
If authorized for use, it would be a groundbreaking treatment. Pills are easy to take and can reach a wider audience than monoclonal antibodies, an effective treatment in high demand.
Merck said it stopped the trial early in consultation...